Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy

克拉斯 腺癌 医学 肿瘤科 内科学 化疗 肺癌 队列 回顾性队列研究 阶段(地层学) 临床意义 癌症 生物 结直肠癌 古生物学
作者
Mihály Cserepes,Gyula Ostoros,Zoltán Lohinai,Erzsébet Rásó,Tamás Barbai,József Tímár,Anita Rózsás,Judit Moldvay,Ilona Kovalszky,Katalin Fábián,Márton Gyulai,Bahil Ghanim,Viktória László,Thomas Klikovits,Mir Alireza Hoda,Michael Grusch,Walter Berger,Walter Klepetko,Balázs Hegedűs,Balázs Döme
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:50 (10): 1819-1828 被引量:70
标识
DOI:10.1016/j.ejca.2014.04.001
摘要

Abstract

Background

Platinum-based chemotherapy is the most common treatment in advanced-stage lung adenocarcinoma. Because the clinical significance of KRAS mutational status in this setting has not yet been clearly determined, a mutation subtype-specific analysis was performed in the so far largest cohort of Caucasian patients with KRAS mutant advanced-stage lung adenocarcinoma treated with platinum-based chemotherapy.

Methods

505 Caucasian stage III–IV lung adenocarcinoma patients with known amino acid substitution-specific KRAS mutational status and treated with platinum-based chemotherapy were included. The correlations of subtype-specific KRAS mutations with smoking status, progression-free and overall survival (PFS and OS, respectively) and therapeutic response were analysed.

Results

Among 338 KRAS wild-type, 147 codon 12 mutant and 20 codon 13 mutant patients, there were no mutation-related significant differences in PFS or OS (P values were 0.534 and 0.917, respectively). Eastern Cooperative Oncology Group (ECOG) status and clinical stage were significant independent prognostic factors. KRAS mutation showed a significant correlation with smoking status (P=0.018). Importantly, however, G12V KRAS mutant patients were significantly more frequent among never-smokers than all other codon 12 KRAS mutant (G12x) subtypes (P=0.016). Furthermore, this subgroup tended to have a higher response rate (66% versus 47%; P=0.077). A modestly longer median PFS was also found in the G12V mutant cohort (233days; versus 175days in the G12x group; P=0.145).

Conclusions

While KRAS mutation status per se is neither prognostic nor predictive in stage III–IV lung adenocarcinoma, subtype-specific analysis may indeed identify clinically relevant subgroups of patients that may ultimately influence treatment decisions.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
被迫做科研的老登完成签到,获得积分10
刚刚
daomaihu发布了新的文献求助100
1秒前
张维完成签到,获得积分10
1秒前
pjx完成签到,获得积分10
2秒前
学必困完成签到 ,获得积分10
2秒前
3秒前
搜集达人的应助被初景采纳,获得10
4秒前
九天春雪发布了新的文献求助10
5秒前
coco完成签到 ,获得积分10
5秒前
刘刘宇航发布了新的文献求助10
6秒前
6秒前
风移完成签到,获得积分10
6秒前
Jasper的应助被11采纳,获得10
8秒前
初景发布了新的文献求助10
8秒前
9秒前
桐桐的应助被xiaoxuey采纳,获得10
9秒前
隐形曼青的应助被敏感墨镜采纳,获得10
11秒前
11秒前
12秒前
12秒前
cmwxh发布了新的文献求助10
14秒前
16秒前
bw完成签到,获得积分10
17秒前
为467u发布了新的文献求助10
17秒前
18秒前
滴滴答答发布了新的文献求助10
18秒前
hx完成签到,获得积分10
18秒前
u110发布了新的文献求助10
18秒前
pjx关注了科研通微信公众号
20秒前
zxx完成签到,获得积分10
20秒前
21秒前
daomaihu发布了新的文献求助100
22秒前
wangmaosen完成签到,获得积分10
23秒前
真实的采白完成签到 ,获得积分10
23秒前
落幕完成签到 ,获得积分10
23秒前
11发布了新的文献求助10
23秒前
贤箪发布了新的文献求助10
25秒前
研友_VZG7GZ的应助被壮观雁易采纳,获得10
25秒前
风趣青槐发布了新的文献求助10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184336
求助须知:如何正确求助?哪些是违规求助? 9573358
关于积分的说明 21830993
捐赠科研通 7781367
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558401
邀请新用户注册赠送积分活动 2480846